Getting To $80 Bil.: PhRMA Expects Mix Of Drug Rebates And Fees In Senate Finance Bill
This article was originally published in The Pink Sheet Daily
In addition to the announced discount for drugs in the Part D donut hole, PhRMA anticipates the Senate Finance Committee's bipartisan bill will seek rebates and fees from pharmaceutical manufacturers.
You may also be interested in...
The Congressional Budget Office has put a value on the net savings that would accrue to the federal government through drug rebate and discount provisions in the pending House health care reform bill: $48 billion over 10 years
Higher drug rebates to Medicaid, Medicare under discussion, as are savings from follow-on biologics.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.